A new preclinical candidate drug with the potential to treat visceral leishmaniasis, one of the world’s major neglected diseases, has been discovered through a close collaboration between the University of Dundee, GSK and Wellcome.
The African trypanosome causes African sleeping sickness, a hideous disease transmitted by the tsetse fly that, untreated, leads to character disintegration, comma and death. The trypanosome parasite evades the patient’s immune system by ‘antigenic variation’, which is the swapping one protective surface coat for another.
We are seeking a highly creative, proactive and energetic individual to take up a new post of Lead for the Drug Discovery Innovation Project (DDIP) at the Wellcome Centre for Anti-Infectives Research (WCAIR), University of Dundee.
A new study entitled “Proteomic Analysis of the Cell Cycle of Procylic Form Trypanosoma brucei” has just been published in Molecular and Cellular Proteomics (Crozier et al., 2018, Mol Cell Proteomics 2018 17: 1184-1195). This study resulted from a collaboration between the laboratories of Mike Ferguson (BCDD) and Angus Lamond (GRE). Trypanosoma brucei is an evolutionarily divergent eukaryotic protozoan parasite that causes human and animal trypanosomiasis (also called ‘sleeping sickness’) in sub-Saharan Africa.
Scientists from the University of Dundee will swap lab coats for hiking boots this weekend as they take on one of Scotland’s greatest wildlife trails for charity.
A team of four scientists from the University’s School of Life Sciences, hope to finish the 52 mile Cateran Trail within just five days as they aim to raise funds for Cats Protection and Re-Act Scotland.
At the Wellcome Centre for Anti-Infectives Research, we have made an exciting discovery about a group of life-threatening parasites.
An exciting new long-term collaboration has been launched between Dundee Rep Theatre and the School's Wellcome Centre for Anti-Infectives Research where together they will develop a series of innovative and diverse engagement and performance opportunities for local communities.
The Drug Discovery Unit (DDU) will collaborate with the not-for-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) and GlaxoSmithKline (GSK) in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
Contemporary biological research is usually discussed in relation to biomedical research and applications.
Kevin Read and Simon Arthur have been promoted to Personal Chair (Professor) as part of the 2017 Annual Review process for academic staff. Kevin Read will become Professor of Quantitative Pharmacology while Simon Arthur will be Professor of Immune Signalling.
“I would like to congratulate both Kevin and Simon on their well-deserved promotions,” said Professor Julian Blow, Dean of Research in the School of Life Sciences. “Both have made significant contributions to their respective fields over a sustained period of time as well as contributing to teaching our undergraduates.”
